Lindis Blood Care Announces Success in REMOVE Clinical Study with CATUVAB® for Cancer Surgeries

Lindis Blood Care GmbH revealed promising results from its REMOVE clinical study on April 22, 2024, marking a significant advancement for autologous blood transfusions in cancer surgeries with its CATUVAB® device. The study enrolled over 130 patients, providing substantial data that affirmed the device's effectiveness and safety.

The REMOVE study focused on the CATUVAB® device's ability to eliminate malignant cells from intraoperative salvaged blood, a crucial step in preventing metastasis during blood transfusions back to cancer patients. The device successfully met all primary and secondary endpoints with high statistical significance, indicating reliable tumor cell removal and a reduction in cytokine levels associated with surgery-related trauma.

With these positive results, the company is now advancing towards obtaining market authorization through CE Mark in Europe and FDA approval in the US. This development could potentially establish CATUVAB® as an innovative standard in the management of intraoperative blood for cancer surgeries. The detailed study results were presented at the NATA24 Annual Symposium in Bologna and will be submitted for publication in a peer-reviewed journal.